Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research Report>CLSA Slightly Cuts SINOPHARM (01099.HK) TP to $27, Rating Buy
Recommend 2 Positive 3 Negative 3 |
||||
|
||||
|
SINOPHARM (01099.HK) showed gradual improvement in its 4Q23 results, as the impact from China's anti-corruption in pharma sector gradually subsided by the end of 2023, CLSA issued a research report saying. The Company's revenue rose 3.9% QoQ, while net profit inclined 48.5% QoQ to RMB3 billion. According to the report, the Company focuses on profit expansion, which is expected to be driven by its emerging business in medical device manufacturing. Therefore, CLSA reiterated rating at Buy, and slightly cut its target price from $27.1 to $27. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
